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Abstract
Background: Women who are notified they carry a BRCA1/2 mutation are presented with surgical options to
reduce their risk of breast and ovarian cancer, including risk-reducing mastectomy (RRM) and risk-reducing
oophorectomy (RRO). Growing evidence suggests that a sub-group of women do not make decisions about RRM
and RRO immediately following genetic testing, but rather, consider these decisions years later. Women’s
perspectives on the timing of these decisions are not well understood. Accordingly, the purpose of this research
was to describe how women construct the ‘right time’ to consider decisions about RRM and RRO.
Methods: In-depth interviews were conducted with 22 BRCA1/2 carrier women and analyzed using qualitative,
constant comparative methods.
Results: The time that lapsed between receipt of genetic test results and receipt of RRM or RRO ranged from
three months to nine years. The findings highlighted the importance of considering decisions about RRM and RRO
one at a time. The women constructed the ‘right time’ to consider these decisions to be when: (1) decisions fit
into their lives, (2) they had enough time to think about decisions, (3) they were ready emotionally to deal with
the decisions and the consequences, (4) all the issues and conflicts were sorted out, (5) there were better options
available, and (6) the health care system was ready for them.
Conclusions: These findings offer novel insights relevant to health care professionals who provide decision
support to women considering RRM and RRO.
Background
Genetic testing for mutations in the BRCA1 and BRCA2
genes has increasingly become available to individuals
since the discovery of these genes over 14 years ago
[1,2]. Those women found to carry BRCA1/2 mutations
are at markedly increased probability of developing her-
editary breast and ovarian cancer (HBOC), with their
lifetime risk of breast cancer between 45% and 88%, and
their risk of ovarian cancer ranging from 11% to 65%
[3-5]. When unaffected women are notified that they
have a BRCA1/2 mutation, they are presented with a
range of HBOC risk-reducing options including risk-
reducing mastectomy (RRM) and risk-reducing oopho-
rectomy (RRO). However, there is growing evidence that
a sub-group of women do not make decisions about
RRM or RRO immediately after genetic testing, but
rather, prolong these decisions for months or years
[6-9]. Women’s experiences with RRM and RRO have
begun to be described [10-12], but their perspectives on
the timing of these decisions are not well understood.
The purpose of this study was to describe how women
who carry BRCA1/2 mutations construct the ‘right time’
to consider decisions about risk-reducing surgeries.
Background Literature
Women found to carry a BRCA1/2 mutation are faced
with difficult decisions about how to manage their ele-
vated HBOC risk. Breast cancer screening is recom-
mended to these women as a means of identifying
cancers at an early stage when the prognosis of treatment
is good, thus reducing the risk of dying from cancer. The
most effective means of preventing breast cancer is
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any medium, provided the original work is properly cited.through RRM, the surgical removal of healthy breast tis-
sue prior to the development of cancer, with the option
of reconstructive surgery. However, RRM is considered
controversial because of the potential for psychological
harm. It is, thus, generally framed as a woman’s personal
decision to be discussed with her health care professional
[13]. As there is no evidence that ovarian cancer screen-
ing is effective in reducing mortality, it is currently
assumed that RRO is the best form of risk management.
As such, RRO, the surgical removal of the fallopian tubes
and ovaries, is commonly recommended to women once
childbearing is complete [13].
Women are encouraged to make decisions about RRM
and RRO when they receive their genetic test results.
However, there is evidence that some women are delay-
ing these decisions. In previous research, there were
women who underwent RRO and/or RRM years after
receiving their genetic test results [6-9]. In the largest of
these studies, which included 297 women who had RRO
and 113 women who had RRM, the average time from
genetic testing to risk-reducing surgery was 1 year [9].
Yet, some of these women had RRO up to 7 years later
and RRM more than 8 years later. For women in
another study who previously had a mastectomy to treat
breast cancer, the mean time that elapsed between their
primary surgery and contralateral RRM was 3.5 years
[14]. The amount of time between receipt of genetic test
results and risk-reducing surgery has raised questions
about why women are not acting promptly to reduce
their risks, and concerns that the full benefits of genetic
testing are not being realized.
It has been suggested that medical, physical, psycholo-
gical, and social context factors influence the timing of
decisions and use of risk-reducing options. Women’s
childbearing and menopausal status have been reported
to have a substantial bearing on how women frame the
optimal timing of these decisions, as have women’s rela-
tionships and their responsibilities to family members,
friends, and employers [7,15-18].
The psychological consequences of genetic testing,
including anxiety, distress, and worry, may dramatically
influence women’s abilities to make risk-reducing deci-
sions, as well as the nature of the decision-making pro-
cess. Although these psychological symptoms decline
over time for the majority of mutation carriers [19-22],
significant psychological distress can persist for others
[22,23]. Moreover, researchers have reported a positive
relationship between distress, anxiety, and worry, and
decisions about RR strategies [24-30].
When positive BRCA1/2 test results are disclosed,
women are also faced with interpreting complex and
emotion-laden information. Women have reported
spending much time reviewing information and seeking
additional sources of information and advice in an
attempt to resolve their questions about the potential
impact of RRM on their lives [31]. In one study, the
lack of absolutes about when, or if, the women would
develop HBOC led to uncertainty about the right time
to make RRM and RRO decisions [32]. Moreover,
BRCA1/2 carriers have expressed a need to consider
relevant information in the context of their individual
experiences, perceptions, and psychosocial needs [33].
It is also important to acknowledge that once women
receive their genetic test results they may encounter
barriers and delays accessing health services that are
central to decisions about risk-reducing surgery and
receipt of risk management choices. For example, in
Canada obtaining consultations with specialized health
care professionals may take months and even years,
while in the United States the financial costs of health
services or the lack of health insurance may be prohibi-
tive. Women in rural settings may experience additional
barriers to treatment including costs of travel and time
away from employment [32].
Although previous research provides important
insights related to risk management decision making,
women’s perspectives related to the timing of decisions
has not been systematically studied. With few excep-
tions, the focus of research to date has been guided by
theoretical perspectives and assumptions that have not
adequately captured the complexity of women’s decision
making [18], or their perspectives on the importance of
making timely decisions and factors that influence
timing. A few studies have described women’s decision-
making processes about risk-reducing surgery as
complex, dynamic, and prolonged [16,31]. In a case
s t u d yt h a ti n v o l v e di n - d e pth interviews with three
women over one year, researchers tracked how women’s
thoughts and decisions about RRM changed over time,
and the time they needed to achieve a level of comfort
with decisions that they were able to follow through
with [31]. It is essential that health care professionals
consider women’sp e r s p e c t i v e so nt h e‘right time’ to
make these decisions given the potential psychological
implications of making untimely decisions, as well as
the implications of delaying RRM and RRO with regard
to women’s morbidity and mortality. A better under-
standing of women’s perspectives is also needed to
guide the provision of RRM and RRO decision support,
as well as the development of decision support interven-
tions that address the complex needs faced by women at
high risk for HBOC.
Methods
This study was conducted in the context of a larger
grounded theory study aimed at developing an in-depth
theory of women’s decision making regarding HBOC
risk-reducing strategies [32]. Qualitative methodological
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bin [35], and Sandelowski [36] were used to develop
descriptions of how women construct the ‘right time’ to
consider decisions about RRM and RRO.
Study Participants
The University of British Columbia behavioral research
ethics board approved this research. Participants were
recruited through a hereditary cancer program in British
Columbia, Canada. Staff at the hereditary cancer pro-
gram distributed a letter of invitation to potential study
participants by mail or in-person at genetic counseling
appointments following receipt of their genetic test
results or the high-risk clinic. The women who
expressed an interest in the study by mailing a signed
consent to contact form to the research team were then
contacted by telephone, wherein they were given further
details about the research, screened for eligibility, and
scheduled for an interview if they consented to partici-
pate. Women who received positive BRCA1/2 genetic
test results, were older than 18 years of age, and English
speaking, were included in this study. Women who were
currently undergoing diagnostic testing for cancer or
were receiving cancer treatments were excluded.
In this Canadian hereditary cancer program, women
undergo genetic counseling before and after genetic test-
ing, wherein they receive oral and written information
about HBOC risk-reducing strategies. RRO is recom-
mended to women once childbearing is complete, and
RRM is not recommended, but rather, is framed as a
personal decision to be discussed with a health profes-
sional. Women found to carry a BRCA1/2 genetic muta-
tion are also advised to undergo breast cancer screening
at the high-risk clinic every six months, and although
formal decision support is not systematically provided
during these appointments, risk-reducing surgery is
often discussed. If women express an interest in risk-
reducing surgery they are then referred to a surgeon for
a consultation.
The demographic characteristics of the 22 participants
are illustrated in Table 1. The mean age of participants
was 51 years of age (ranging from 28 to 80 years). The
majority of women were Caucasian, college or university
educated, and employed either full- or part-time. Most
of the women were married, and just over half had chil-
dren. Five women had a history of breast cancer.
Data Collection Procedures
In-depth interviews, lasting 45 to 90 minutes, were con-
d u c t e da tat i m ea n dp l a c ec o n v e n i e n tt ot h ep a r t i c i -
pants following receipt of written informed consent. All
interviews were digitally recorded and transcribed verba-
tim. Each woman in this research was assigned a pseu-
donym in order to maintain her anonymity. The initial
interviews began with open-ended questions to elicit
participants’ perspectives and were designed to draw out
the underlying process of decision making, which also
captured the timing of decisions [34]. For example, we
asked the women to describe their perspectives of: the
factors (medical, physical, psychological, and family con-
text) that influenced when decisions about risk-reducing
surgeries were considered; how their relationships with
family and health care professionals influenced when
decisions about risk-reducing surgeries were considered;
how organizations, institutions, or the health care sys-
tem influenced when decisions about risk-reducing sur-
geries were considered; and how the appropriate time to
consider risk-reducing surgeries changed over time. As
data analysis proceeded, the questions became more
specific to fill in gaps, explore important areas in greater
depth, and verify emerging findings [34].
Data Analysis Procedures
Data analysis involved the constant comparison of data
from different participants, and across incidents and
themes [34,35]. The transcripts were read numerous
Table 1 Characteristics of Study Sample
Characteristics Frequency (%)
Marital Status
Married/common-law 17 (77)
Single/separated/divorced/widowed 5 (23)
Ethnicity
Anglo-Saxon 11 (50)
Ashkenazi Jewish 6 (27)
Other 5 (23)
Education
Some college and above 15 (68)
High school and below 7 (32)
Employment
Employed 18 (82)
Unemployed/homemaker/retired 4 (18)
Household annual income (Canadian)
Less than 40,000 4 (18)
$41,000 - 80,000 8 (36)
Greater than $80,000 10 (46)
Children
Have children 12 (55)
No children 10 (45)
Time since genetic testing
Less than 1 year 5 (23)
1-4 years 4 (18)
Greater than 5 years 13 (59)
Cancer history
Previous breast cancer history 5 (23)
No previous breast cancer history 17 (77)
Note.N=2 2
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relevant to the research questions were identified using
an inductive approach [37]. Each woman’s decision-
making experience was captured in a narrative summary
noting what risk management decisions were made and
when, as well as whether these decisions changed over
time. In addition, interview data related to the timing of
decisions was identified, and coded for retrieval and in-
depth analysis using the data management software pro-
gram NVivo. One author (A.F.H.) reviewed these data to
identify themes that recurred within the interviews and
were evident in multiple women’s accounts. During the
next phase of analysis, all four members of the research
team reviewed and discussed the themes. The team
compared the data related to each theme, raised ques-
tions to further the analysis, and identified the relation-
ships within and between the themes, thereby helping to
refine these thematic categories. This continued until all
ideas, interpretations, and themes were accounted for in
the final description.
Results
Decisions about risk-reducing surgery evolved over
m o n t h sa n de v e ny e a r sf o rm a n yo ft h ew o m e ni nt h i s
study. At the time of being interviewed, all of the
women were having biannual cancer screening through
the hereditary cancer program high-risk clinic. Thirteen
of 19 women with ovaries (3 women previously had
bilaterally salpingo-oophorectomy to treat medical con-
ditions) had undergone RRO and three of the 22
women with breasts had undergone RRM. The time that
lapsed between receipt of genetic test results and receipt
of risk-reducing surgery ranged from three months to
nine years. Of the women who had not undergone risk-
reducing surgery, the majority had not ruled out consid-
ering these decisions in the future. It was important to
the women for decisions about RRM and RRO to be
made one at a time. Moreover, the women constructed
the ‘right time’ to consider decisions about risk-reducing
surgery to be when: (1) decisions fit into their lives, (2)
they had enough time to think about decisions, (3) they
were ready emotionally to deal with the decisions and
the consequences, (4) all of the issues and conflicts were
sorted out, (5) there were better options available, and
(6) the health care system was ready for them.
One Decision at a Time
The women in this study, with one exception, did not
engage in decisions about RRM and RRO concurrently.
Rather, they prioritized their decisions and then consid-
ered them one at a time. The decisions the women
deemed most relevant to them, less disruptive to their
lives, uncomplicated, associated with fewer negative phy-
sical and emotional consequences, and supported by
others, were made first. Karen, a 53-year-old woman
who received her genetic test results three years pre-
viously recalled her reaction to the options of RRM and
RRO:
When I saw Dr. [name] she started talking about
mastectomies. And I said, “Look, I’m going to deal
with the ovarian thing first, that’sw h a th a sm a n i -
fested in my family most and been the most lethal.
And the breast thing, there’s good screening tools
out there and I’m not going to deal with that right
this minute. I want to deal with the ovarian thing
first. First things first.”
In keeping with this, most of the women considered
decisions about RRO first, and then RRM. The women
also commonly made “temporary” decisions and then
revisited their decisions later on, when they thought it
was the ‘right time.’ Leslie, a 55 year old woman who
received her genetic test results two years previously,
described her approach to considering risk-reducing
surgery:
Well I basically had gone from, in the summer, say-
ing I’m going to focus on my ovaries, get that done,
worry about the breast thing, and then getting really
enthusiastic about maybe doing the breast stuff,
going and seeing the plastic surgeon and being
totally turned off, and going totally against it [RRM].
And then I guess this year it came up again, when I
had another mammogram in early February and
then they wanted to do a bigger magnification of it.
And then that started me thinking again about this.
Am I making the right decision? Is this really safe to
do this route, the high surveillance? But, I’ve reexa-
mined it again, and I still feel that it’s premature to
make a decision.
The women’s experiences with cancer screening and
making or following through with risk-reducing surgery
decisions had a significant influence on when subse-
quent decisions were considered. A number of women
felt “protected” from cancer because they had faith in
the efficacy of screening and believed that if detected
early, cancer was easily treated. The reassurance asso-
ciated with screening resulted in many women feeling
comfortable “sticking with screening” for the time being
and postponing RRM and RRO decisions. However,
anxiety, physical discomfort and experiences of finding
“something suspicious” during screening prompted a
revisiting of their risk-reducing surgery decisions. This
was also the case when women’s negative experiences
with RRO resulted in their re-evaluating the ‘right time’
to consider RRM.
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The women wanted to fit decisions about risk-reducing
surgery into their current and future life plans. For
example, Rose, a 39-year-old woman who had known
her genetic test results for five years, questioned how
RRM would fit into her active lifestyle:
I’m still thinking about the mastectomy [RRM]. I
know that no implants can make life a little rough
too. If you’re an active person like me and you
s p e n dal o to ft i m ea tt h ep o o lb u ty o uh a v eap r o -
blem with your self-image then you might not go to
the pool, right? Or you might not do the sports that
you might normally have done, right? And at this
point I’m not spending a lot of time at the pool but
pre kids I was doing triathlons and stuff. So if I get
back into that kind of a lifestyle, would I be totally
comfortable? So I don’tt h i n kI ’mr e a d yt og i v et h a t
up yet.
For some, this meant postponing decisions until
important events occurred, or phases of their lives com-
pleted. Younger, single women considered the impor-
tance of their ovaries to appearing youthful and breasts
to appearing attractive to potential partners. The
women interested in dating, starting intimate relation-
ships, and finding a partner preferred to postpone deci-
sions about risk-reducing surgery until they were in a
serious relationship. Scarlet, a 37-year-old woman who
received her genetic test results nine years ago described
why RRM did not currently fit into her life:
My mom is very proactive and encourages me to go
and have prophylactic mastectomy. But she’sn o t
l o o k i n ga ti tt h ew a yI ’ml o o k i n ga ti t .I t ’s always in
t h eb a c ko fm ym i n dt h a to n ed a yw h e nI ’mo l d e rI
may do that [RRM], but not now. Not when I’m just
in a new relationship and I don’t even know if it will
work out. It’s just not the time right now.
Although most married women acknowledged that
their husbands loved them for more than their breasts
and ovaries, some women questioned the effects RRM
a n dR R Ow o u l dh a v eo nt h e i rr e l a t i o n s h i p .I tw a s
important for these women to obtain reassurance from
their partners before they seriously considered risk-
reducing surgery. For some of the women who still
wanted children, or who were not done childbearing,
both RRM and RRO were considered premature. Chris-
tine, a 42-year-old single woman who had known her
genetic test results for five years, recalled how the deci-
sion not to have children was crucial to the timing of
her decision about RRO:
What I had to come to terms with mostly before I
could think about the surgery [RRO] was that I
wasn’t going to have kids. Once I had come to terms
with that, and then basically getting to the point
where I don’tw a n tt oh a v ec h i l d r e n ,m a d ei tal o t
easier for me. I never had a partner for very long
and I don’t have a lot of money. Unless you can
really provide for a child it doesn’t seem right.
These women felt reassured postponing their decisions
about RRO because this was congruent with the heredi-
tary cancer program recommendations to wait to make
this decision until childbearing was complete. However,
some women contemplated altering their life plans by
looking into alternatives for having children (i.e., adop-
tion or “freezing their eggs” and undergoing in-vitro fer-
tilization) and engaging in family planning discussions
with their partners to determine whether changing their
pre-existing plans was an option.
The women also constructed the ‘right time’ to con-
sider decisions about risk-reducing surgery to be when
these decisions aligned with their perception of who
they were at particular times and phases of their lives.
This included how the women saw themselves (e.g., as
younger and older), their bodies (e.g., as fertile and
post-menopausal), and themselves in relation to others
(e.g., as single, an intimate partner, and a widow), in the
present and the future.
When I Have Taken Enough Time to Think About
Decisions
The women needed to have enough time to deliberate
about risk-reducing surgery decisions so that they felt
ready and able to make these decisions. Taking time to
carefully consider these “big” and “complicated” deci-
sions was not only considered by the women to be
necessary, but was encouraged by health care profes-
sionals, family, and friends. Maureen, a 48-year-old
woman who had known her genetic test results for five
years, recalled the advice given to her by her family phy-
sician:
She [physician] just said. “You know it [RRM] is
irreversible, so once you’ve made that decision,
there’s no turning back. So take your time, and
weigh the pros and cons.” And there are just so
many pros and cons and it’s huge. I mean this deci-
sion is really huge.
The women had many questions and things to think
about, such as the intricate details of surgery and recon-
struction, possible surgical side effects and complica-
tions, and the consequences of surgery on their feelings
Howard et al. BMC Women’s Health 2010, 10:24
http://www.biomedcentral.com/1472-6874/10/24
Page 5 of 12of femininity, body image, sexuality, and self-esteem.
The ‘right time’ to consider these decisions was when
the women had obtained answers to all of their ques-
tions, and thoroughly considered all facets of their possi-
ble options. This involved the use of a variety of
decision-making approaches over time, including enga-
ging with others, looking inwards, making sense of the
numbers about risks, and weighing the pros and cons,
as described in detail elsewhere [32].
The ‘right time’ to consider decisions about risk-redu-
cing surgery was also when the women could concentrate
their energies on making these decisions. Because some
women’s lives were busy, they postponed their decisions
until they could give them their full attention. Dealing
with other existing health problems, such as cardiovascular
disease, chronic fatigue syndrome, or fibromyalgia, took
precedence over considerations about preventive surgery,
as did providing care to ill family members. For example,
Coral, a 51-year-old breast cancer survivor, had postponed
making a decision about RRM for six years because she
was too busy providing care to her ailing parents and then
o r g a n i z i n gt h ef a m i l ya f f a i r so n c et h e yp a s s e da w a y .“I
wasn’t ready [to decide about RRM] with all the responsi-
bilities that I had to take care of. So now I just have myself
and I don’t have anybody to worry about.”
When I am Ready Emotionally to Deal with Decisions
T h ew o m e np e r c e i v e dt h a tt h e yn e e d e dt i m et od e a l
with the emotional consequences of carrying a BRCA1/2
mutation before they could make decisions about risk-
reducing surgery. At times, the women were preoccu-
pied with related anxiety, distress, and worry, which not
only interfered with their everyday lives, but also pre-
vented them from feeling capable of fully engaging in
decision making. Christine, a 42-year-old single woman
who had known her genetic test results for five years,
recalled feeling too overwhelmed to engage in a yearly
conversation about RRO with her physician at the her-
editary cancer high-risk clinic:
It’s so unconscious or irrational the kind of fear that
you feel, that I didn’t even show up for my appoint-
ment [at the high-risk clinic]. And that’s so not like
me and I was in trouble with Dr. [name]. She had to
rebook and see me on a prostate day, which was not
good. So that was one thing where I just kind of
shut down and I think that day I just stayed home
and cried and I was really upset. But nothing feels
very conscious. It’s very emotional.
Feeling emotionally overwhelmed led some women to
feel uncertain and apprehensive about their abilities to
make risk management decisions. Postponing these deci-
sions gave the women the time they needed to cope
with their emotions, get accustomed to the ideas of
RRO, RRM, and breast reconstruction, and to come to
terms with the consequences of these decisions. Two
women sought professional psychological support to
help them cope with their anxiety and depression
brought on following genetic testing. The women con-
structed the ‘right time’ to consider these decisions to
be when they had sufficiently addressed their anxiety,
distress, and worry to be able to engage in decision
making without feeling overwhelmed.
When all of the Issues and Conflicts are Sorted Out
The women indicated that they needed to address the
issues and conflicts that the decisions raised before they
could finalize decisions about risk-reducing surgery.
Sorting out the issues and conflicts within themselves,
with their family, and with health care professionals
often took time. Inner conflict was the result of the
women feeling uncertain about their HBOC risk, having
numerous questions about risk-reducing surgery and
breast reconstruction, and encountering difficulty with
weighing the pros and cons of these decisions. For
example, when Lauren, a 40-year-old woman, consulted
a surgeon intending to have RRO, she was informed she
would have to take hormone replacement therapy post-
operatively - “So then the hormones would increase my
chance for breast cancer, and so there was all that con-
flict.” Although gathering information and advice was
helpful, at times this resulted in obtaining new informa-
tion that needed to be considered in decisions and
added further complexity to decision making. In these
situations, women were often left feeling more confused
and conflicted about the decisions they were trying to
make. For example, Leslie, a 55 year old woman who
received her genetic test results two years previously,
described feeling conflicted about breast reconstruction
upon learning about the details of the procedure:
But then I find out that they put it [the implant]
behind your pectoralis major muscle. They don’t put
it in your skin where your breast was. They put it
behind your pectoralis major, between that and your
chest wall. So then they have to fill this thing with
water and stretch the muscle every two weeks.
That’s what the expansion thing is. They say it’sf o r
your skin on all the websites. No, it’s for the muscle,
to accommodate this lump. And I just thought that’s
ridiculous. I couldn’t believe that’sw h a tt h e yd i d .S o
now I don’t know what to do.
There were also issues and conflicts involving family
members that the women wanted resolved before they
felt comfortable finalizing their decisions. Some family
members voiced their concerns about risk-reducing
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right course of action for the women to take. Wanting
to remain sensitive to family members concerns and
opinions, some women postponed their decisions or fol-
lowed through with their decisions at a later time. For
example, Lilith, a 39-year-old woman, decided to have
RRO and RRM a couple of months after she was found
to carry a BRCA1/2 mutation. But, she postponed RRM
indefinitely and RRO for over a year because her mother
was upset and disagreed with her decision. Sorting
through family conflict also involved taking the time to
provide explanations and information, and to try and
convince family members that the decision the women
were leaning towards was the best decision for them.
Sorting through issues with health care professionals
was also an essential step to settling on decisions about
risk-reducing surgery. Seeking second and third medical
opinions in order to investigate alternative options, dou-
ble check recommendations, gather more information,
and obtain advice took time. Furthermore, these interac-
tions complicated decisions when these professionals
provided advice that conflicted with the recommenda-
tions or advice they previously received. Often times,
disagreements and conflict with health care profes-
sionals stemmed from disparate views about what was
the most important, acceptable, or desirable decision.
For example, at the time of interview Coral’s decision to
have RRM and reconstruction had been prolonged
approximately six months because her preferences for
reconstruction differed from those of her physician:
Right now we’re arguing about the size [that my
reconstructed breast should be]. He [physician] says
well, you know with the breadth of your chest you
h a v et ob eaCc u p .A n dI ’mg o i n g ,“Oh please,
make them smaller because you have no idea what
it’s like. You carry twenty pounds on your chest and
then tell me that you want me to be the same size.”
W e l lIh a v et h es u r g e o no nm ys i d en o w .S h es a y s ,
“It’s men, you know what it’sl i k e . ” I mean he is the
professional so I said, “Why do you think I’ll look
freakish? I want a B cup. I see no difference between
a B or a C cup as far as my chest wall goes.” So I’m
just goanna stick with it.
When there are Better Options
Some women thought the time was not yet right to con-
sider making decisions about risk-reducing surgery
because not enough was known about hereditary cancer.
This was reflected in the comments made by Jen, a 53-
year-old woman who had known she carried a BRCA1/2
mutation for five years: “I mean we’re still talking about
having a mastectomy in the future, but I don’t have any
breast cancer in my family so I’m thinking maybe they
don’t know enough about these genetic mutations yet.”
The women considered the cancer genetics field to be a
young science characterized by new technology, numer-
ous unanswered questions, and evolving knowledge.
Reflecting on the past, the women perceived there to be
more options now than ever before to reduce their risk
of developing or dying from HBOC, and they expected
this trend to continue. As a result, the women had faith
in scientific and medical progress and perceived the
‘right time’ to consider decisions about risk-reducing
surgery to be when new scientific evidence emerges and
less invasive, less drastic, better tolerated, and more
acceptable medical and surgical options and techniques
become available and accessible. For example, Leslie
described her decision to wait to consider RRM until
different breast reconstruction techniques were offered
in Canada:
I’ve got another friend who has the gene. She’sf r o m
Iran and her sister in Iran had breast cancer, and
had the mastectomy and reconstructive surgery. And
over there they have a very highly sophisticated plas-
tic surgery industry, which I didn’t know about, and
she just had the implant put underneath the skin,
a n di tw a sf i n e .S oI ’mj u s to nh o l du n t i lt h e ys t a r t
doing that [reconstructive surgery] here.
Some women also relied on the guidance of experts to
help them determine when better options would warrant
revisiting their previous decisions. This was evident in
the explanation provided by Maurice, a 65-year-old
woman who received her genetic test results nine years
previously:
The consensus of the cancer program and my doctor
w a st h a ti t[ R R M ]w a s n ’t necessary. And if it’sn o t
necessary I’m not going to run out and do it. But if
anyone thought it would really be a good idea for
me, I’m prepared to do it. I have made the decision
to stick with screening for now, and I’m letting that
decision sit until I hear from someone who knows
that there could be a better decision.
When the System is Ready for Me
The women’sc o n s t r u c t i o n so ft h e‘right time’ to con-
sider decisions about risk-reducing surgery were also
influenced by perceptions about when the Canadian
health care system could accommodate their choice. A
number of women engaged in ongoing conversations
about risk-reducing surgery during biannual breast can-
cer screening appointments at the hereditary cancer
high-risk clinic. They had faith in the existing referral
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them decide about RRM and RRO. Most women were
not upset that referrals to surgeons took up to a year
because this gave them time to think more carefully
about risk-reducing surgery, as evident in Coral’s
description:
When I saw Dr. X at the cancer agency for my
check up she said, “Well, I can set you up to talk to
the surgeon and read some information on it.” And
if I wanted to she could put me in touch with other
people who had the surgery. A lot of time went by
in-between but I wasn’t ready. Waiting to have the
chat, I pretty much had time to think about it. And
I knew that was what I was going to do. I think my
mind was made up before I even saw the surgeon.
Wanting to “get things over and done with” once they
had made their decisions, some women felt disappointed
and anxious when the system was not ready for them.
The lack of seamless care also led some women to post-
poned their decisions, believing the Canadian health
care system could not meet their needs, as described by
Lauren, who knew her BRCA1/2 carrier status for four
years:
My decision process, and my sister’s decision pro-
cess, would be a lot different if we could have the
reconstruction done at the time as the mastectomy.
It’s huge. My sister actually has opted to have both
of her breasts removed prophylactically and to have
the reconstruction later, and she’s been on a waiting
list for two and a half, three years now. It just
doesn’t make sense to me to do the surgeries twice.
And why can’t we go with dignity and grace? You
know, if I’me v e ra b l et oh a v er e c o n s t r u c t i o na tt h e
same time, I’d seriously consider the surgery. It
would make my decision easier.
Discussion
The study findings described how women who carry a
BRCA1/2 mutation construct the ‘right time’ to make
decisions about RRM and RRO. It was important for the
women in this study to consider decisions in the context
of their lives, take enough time to deliberate, cope with
their emotions, sort through issues and conflicts, wait
for better medical and surgical options, and factor in
the readiness of the health care system. These findings
p r o v i d ep o s s i b l ee x p l a n a t i o n sf o rt h et i m ef r a m e s
between genetic testing and risk-reducing surgeries
observed in other studies [6-9].
Of note, the women in this study did not frame their
decision making as “delayed,”“ slow,” or taking “too
long”. This differs from researchers and clinicians who
are of the opinion that risk-reducing surgery is the best
way to eradicate breast cancer risk in BRCA1/2 muta-
tion carriers and have voiced their concern that some
women are waiting too long to decide about RRM and
RRO [38]. These conflicting perspectives appear to stem
from different concerns and priorities associated with
HBOC risk management. On the one hand, some
women perceive prolonging or deferring decisions about
risk-reducing surgery as enhancing their quality of life
and helping them manage the inherent decisional con-
flict. On the other hand, there are also risks with delay-
ing these decisions that cannot be ignored. These
women could develop cancer in the interim. Future
research is needed to understand whether these different
concerns and priorities complicate the provision of
genetic services, and if so, in what capacity.
McCullum and colleagues [31] reported that women
prolonged their RRM decisions while they focused on
quality of life issues, specifically the associated risk of
decreased physical and emotional well-being. For the
women in the present study, the physical consequences
associated with risk-reducing surgery held different
meanings at different phases of their lives. Consistent
with the genetic testing and risk management literature
[16,17,39-41], younger women considered decisions
about RRO and RRM inappropriate because of their life
plans, such as finding a life partner, childbearing and
childrearing. Yet some of the women contemplated
changing these life plans or searching out alternatives,
phenomena previously reported but requiring further
examination [16]. It is possible that these women were
attempting to reconcile their competing desires to have
risk-reducing surgery sooner than later, but also fulfill
important life goals essential to their quality of life.
Attending to dimensions of self other than physical
health has also been found to an important part of the
decision-making process [32].
Emotional well-being also influenced when the study
participants considered risk-reducing surgery decisions.
These women needed time to deal with the emotional
consequences of carrying a BRCA1/2 mutation and con-
sider the implications of risk-reducing surgery before
making final decisions. Rather than rush into decisions
to cope with their distress, anxiety, and worry, these
women prolonged the decision-making process while
they coped with their emotions and also postponed
their decisions until they felt emotionally ready. Women
have previously reported declining genetic testing
because of their desire to protect themselves and their
family from the emotional consequences [42]. In con-
trast, research that examined predictors of RRM and
RRO found anxiety, distress, and worry to be key pre-
dictors of risk-reducing surgery [24-30]. Women have
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risk-reducing surgery represented a strategy for mana-
ging the associated worry and anxiety [15,43]. These dis-
parate findings suggest that emotions of anxiety,
distress, and worry do not always predispose women to
make particular decisions at particular times following
genetic testing. Instead, emotions play a much more
complex role in the timing of women’s decisions related
to RRM and RRO.
In the study by Kenen and colleagues [44], women
who carried a BRCA1/2 mutation vacillated from one
position to the other and took years to make up their
minds about RRM. Most of these women reported
spending a great deal of thought on RRM during this
decision-making process. The research by Kenen et al.
[44], in combination with findings from the present
study, suggests that decisions about risk-reducing sur-
gery are fraught with decisional conflict. Decisional con-
flict occurs when there are: risks or scientific
uncertainty about the benefits and harms, choices with
large potential gains and losses, value tradeoffs in select-
ing a particular course of action, and potential regrets
with the selected option [45]. Tan and colleagues [46]
found that the two most important reasons for women
to postpone RRM were uncertainty about proceeding
with surgery and the need for more risk information.
The lack of conclusive information about the risk of
HBOC and the implications of risk-reducing surgery
were particularly problematic for the women in the pre-
sent study, as reported in other research [28,31,43,47]. It
is, therefore, unsurprising that these women struggled
with uncertainty and were compelled to seek out second
and third medical opinions over time. Further research
is needed to understand the impact of these opinions
and advice on women’s uncertainty and the decision-
making process, as well as how women resolve conflict
when differing opinions are garnered.
The research that has focused on decisions about
BRCA1/2 genetic testing suggests that family members
a r ei n t i m a t e l yi n v o l v e di nt h eg e n e t i ct e s t i n gp r o c e s s ,
before, during, and after their relative decides to go for-
ward with testing [48]. Family relationships are also
affected when women are found to carry BRCA1/2
mutations [48,49]. Researchers have reported that
women who tried to discuss hereditary cancer or risk-
reducing surgery with their families have been met with
resistance, shock, hostility, and additional negative
responses [40,50,51]. This resulted in women self-cen-
soring by pulling back or not talking about cancer for
fear of causing worry or anxiety [51]. In a similar fash-
ion, the women in this research further postponed mak-
ing decisions about risk-reducing surgery because they
wanted to remain sensitive to family members’ concerns
and opinions. They also attempted to resolve family
conflicts and disagreements before they felt comfortable
making RRM and RRO decisions. Future research
exploring family dynamics in relation to decisions about
risk-reducing surgery would broaden our understanding
of these findings.
International differences in the uptake rates of risk-
reducing surgeries have been observed and attributed to
health care providers’ recommendations and continuity
of follow-up, as well as cultural variations [52]. For
example, in one study, 344 women who attended a can-
cer genetics clinic in Canada (Quebec), Britian or Great
Britian were found to vary in their preferences regarding
cancer prevention [53]. The authors attributed this var-
iation to cultural differences between countries.
Although it was unclear in this study whether culture
was an influential factor, it was apparent that the struc-
ture of Canadian health services plays a significant role
in when women consider risk-reducing surgery, as do
the barriers women encounter accessing specific services
that they believe would best meet their needs. Although
timely and accessible health care for all Canadians is a
cornerstone of publicly funded health care, patients rou-
tinely encounter significant challenges accessing and
receiving timely, coordinated, and comprehensive care
from interprofessional teams [54]. It appears hereditary
cancer and preventive surgical services are no exception.
In the present study, the extended decision-making pro-
cess was in part a by-product of the health care system
in Canada, wherein the women encountered lengthy
wait times for referrals as well as surgery and breast
reconstruction. The finding that this time lag gave some
women needed time to think more closely about risk-
reducing surgery suggests that women are still engaged
in the decision-making process and possibly preparing
for consultations while they wait. Further inquiry into
the feasibility of offering decision-making support dur-
ing this time is needed.
There are limitations inherent to this research. This
study included participants who were recruited from a
single hereditary cancer centre in Canada. Caution must
therefore be exercised when determining the relevance
of the findings in other settings. As well, the perspec-
tives of older women are underrepresented in this study
s i n c eo n l yo n ew o m a nw a so v e rt h ea g eo f6 5 .M o r e -
over, we did not access any participants with positive
BRCA1/2 test results who chose not to partake in the
recommended HBOC screening. It is possible that the
study participants represent a homogeneous group with
ready access to screening services and beliefs in early
detection. There might also be women who are consid-
ering decisions about RRM and RRO who do not have
contact with health care professionals. Genetic informa-
tion, evidence about the effectiveness of HBOC risk
management strategies, and the availability of online
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changed over the years. Thus, women who received
their BRCA1/2 test results and were availed of the
options of RRM and RRO at different times, particularly
a number of years ago, might have had different kinds
of experiences than women who received their genetic
test results more recently.
Conclusion
In conclusion, women’s perspectives about the appropri-
ate time to consider decisions about risk-reducing sur-
geries have been absent from the scientific literature to
date. Incorporating women’s perspectives on the timing
of these decisions could provide valuable direction for
decision support. The above findings provide evidence
that decision support ought to be accessible when
women want and need the support because some
women prolong or defer decisions to a later time. For
those who are overwhelmed with simultaneously facing
multiple decisions about HBOC risk management, it
may be beneficial to help women prioritize their needs
and to work through each of their decisions when they
feel ready. Some women may require ongoing psycholo-
gical support because they find it difficult to come to
terms with their HBOC susceptibility, as well the ideas
of RRM and RRO. Making this option available to those
women who are interested is crucial. The findings sug-
gest that women consider decisions about risk-reducing
surgery in the context of their life plans, relationships,
medical science, and the health care system. This pro-
vides evidence that broader approaches to decision sup-
port, such as relational or women-centered approaches,
might complement existing services. A relational
approach could assist women with mobilizing support
and resources, communicating with others about HBOC
risk management, and working through interpersonal
issues. A women-centred approach addresses issues
beyond traditional medical interventions, placing health
in its broad social context, and also addresses barriers to
access and respects women’s diversity [55]. Although
risk-reducing surgery decisions are women’s decisions,
women should not be saddled with the burden of tack-
ling barriers to accessing health care services. Health
care professionals, health care organizations, and gov-
ernment must work hard to resolve these challenges.
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